Novel coronavirus infection (COVID-19) — clinical recommendations
https://doi.org/10.30629/0023-2149-2023-101-12-601-606
Abstract
The treatment of patients with a new coronavirus infection (COVID-19) is the cornerstone of practical healthcare. This is due to the widespread and unjustified use of antimicrobial drugs, the use of irrational antiviral therapy schemes. Also, the discussion regarding the use of systemic glucocorticosteroids and monoclonal antibodies continues to this day. In this publication, based on research data and own clinical observations, clinical recommendations for COVID-19 pharmacotherapy are presented.
About the Author
A. A. Zaitsev
Main Military Clinical Hospital named after Academician N.N. Burdenko of the Ministry of Defense of the Russia; Medical Institute of Continuing Education Russian Biotechnological University
Russian Federation
Russian Federation
Andrey A. Zaitsev — Doctor of Medical Sciences, Professor, Chief Pulmonologist of the Ministry of Defense of Russia, Chief Pulmonologist; Head of the Department of Pulmonology with a course in Allergology
105229, Moscow
125080, Moscow
References
1. Avdeev S.N., Adamyan L.V., Baranov A.A., Baranova N.N., Boyko E.A., Briko N.I., Vasilyeva I.A., Goncharov S.F., Danilenko D.M., Drapkina O.M., Zaitsev A.A., Isaeva I.V., Kachanova N.A., Lioznov D.A., Lobzin Yu.V., Maleev V.V., Mamanova N.A. et al. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Temporary methodological recommendations. Moscow, 2022. (In Russian)
2. Zaitsev A.A., Chernov S.A., Kryukov E.V., Golukhova E.Z., Rybka M.M. Practical experience of managing patients with a new COVID-19 coronavirus infection in a hospital (preliminary results and recommendations). Attending physician. 2020;6:76–80. (In Russian)
3. Zaitsev A.A. Letter to the editor. Clinical microbiology and antimicrobial chemotherapy. 2020;22(2):84–86. (In Russian) DOI: 10.36488/cmac.2020.2.84-86
4. Zaitsev A.A., Chernov S.A., Stets V.V., Patsenko M.B., Kudryashov O.I., Chernetsov V.A., Kryukov E.V. Algorithms for the management of patients with a new coronavirus infection COVID-19 in the hospital. methodological recommendations. Consilium Medicum. 2020;22(11):91–97. (In Russian)
5. Jayk Bernal A., Gomes da Silva M., Musungaie D. et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N. Engl. J. Med. 2021:386.
6. Hammond J., Leister-Tebbe H., Gardner A., et al. EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N. Engl. J. Med. 2022;386:1397–408. DOI: 10.1056/NEJMoa2118542
7. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399:1941–1953.
8. Ali K., Azher T., Baqi M., Binnie A., Borgia S., Carrier F.M., Cavayas Y.A., Chagnon N., Cheng M.P., Conly J. et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: A randomized controlled trial. Can. Med. Assoc. J. 2022;194:E242–E251.
9. Johnson R., Vinetz J. Dexamethasone in the management of COVID-19. ВMJ. 2020;370:m2648. DOI: 10.1136/bmj.m2648
10. Munch M., Myatra S. et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA. 2021;326(18):1807–1817. DOI: 10.1001/jama.2021.18295
11. Papamanoli A., Yoo J., Grewal P. et al. High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia. Eur. J. Clin. Invest. 2021;51(2):e13458. DOI: 10.1111/eci.13458
12. Zaitsev A.A., Golukhova E.Z., Mamalyga M.L. et al. Efficacy of pulse therapy with methylprednisolone in patients with COVID19. Clinical microbiology and antimicrobial chemotherapy. 2020;22(2):88–91. (In Russian) DOI: 10.36488/cmac.2020.2.88-91
13. Webb S., Higgins A., McArthur C. Glucocorticoid Dose in COVID-19: Lessons for Clinical Trials During a Pandemic. JAMA. 2021;326(18):1801–1802. DOI: 10.1001/jama.2021.16438
14. Guaraldi G., Meschiari M., Cozzi-Lepri A. et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2:e474–8.
15. Menzella F., Fontana M., Salvarani C. et al. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit. Care. 2020;24:589.
16. Potere N., Di Nisio M., Cibelli D. et al. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study. Ann. Rheum. Dis. 2021;80(2):1–2. DOI: 10.1136/annrheumdis-2020-218243
17. Gupta S., Wang W., Hayek S.S. et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern. Med. 2020 Oct 20. DOI: 10.1001/jamainternmed.2020.6252
18. Hoffman-La Roche Ltd. Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia. Published September 18, 2020. Accessed September 19, 2020. URL: https://www.roche.com/investors/updates/invupdate-2020-09-18.htm
19. Lomakin N.V., Bakirov B.A., Protsenko D.N. et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflamm. Res. 2021;70(10–12):1233–46. DOI: 10.1007/s00011-021-01507-5
20. Gorodin V.N., Moisova D.L., Zotov S.V., Vanyukov A.A., Chumakova Yu.E. Features of proactive anti-inflammatory therapy with levilimab in COVID-19. Infectious diseases. 2021;19(3):14–23. (In Russian) DOI: 10.20953/1729-9225-2021-3-14-23
21. Tavlueva E.V., Ivanov I.G., Lytkina K.A. et al. The use of levilimab in patients with a new coronavirus infection (C0 VID-19) in real clinical practice. Clinical pharmacology and therapy. 2021;30(3):7–13. (In Russian) DOI: 10.32756/0869-5490-2021-3-31-37
22. Zaitsev A.A. Treatment of acute respiratory viral infections. The attending physician. 2008;8:10–13. (In Russian)
23. Okovity S.V., Sukhanov D.S., Zaitsev A.A. Cough with a new coronavirus infection (COVID-19): rational approaches to pharmacotherapy (review). Pulmonology. 2022;32(2):232–238. (In Russian)
24. Zaccone E.J., Lieu T., Muroi Y. et al. Parainfluenza 3-induced cough hypersensitivity in the guinea pig airways. PLoS One. 2016;11(5):e0155526. DOI: 10.1371/journal.pone.0155526
25. Deng Z., Zhou W., Sun J. et al. IFN-γ enhances the cough reflex sensitivity via calcium influx in vagal sensory neurons. Am. J. Respir. Crit. Care Med. 2018;198(7):868–879. DOI: 10.1164/rccm.201709-1813OC
26. Patil M.J., Ru F., Sun H. et al Acute activation of bronchopulmonary vagal nociceptors by type I interferons. J. Physiol. 2020;598(23):5541–5554. DOI: 10.1113/JP280276
27. Zaitsev A.A., Okovity S.V., Miroshnichenko N.A., Kryukov E.V. Cough: Methodological re com mendations for doctors. Moscow: GVKG named after N.N. Burdenko. 2015. (In Russian)
28. Zaitsev A.A. Cough: problems and solutions. Practical pulmonology. 2020;2:78–86. (In Russian)
29. Budnevsky A.V., Ovsyannikov E.S., Feigelman S.N. Study of the effectiveness of levopront in the treatment of unproductive cough. Practical pulmonology. 2021;2:65–74. (In Russian)
30. Maleev V.V., Zaitsev A.A., Yakovlev S.V., Kozlov R.S. et al. On the use of antibacterial therapy in patients with a new coronavirus infection COVID-19. Therapeutic Archive. 2020;11:4. (In Russian)
31. Chedid M., Waked R. et al. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. Journal of Infection and Public Health. 2021;14(5):570–576.
32. Lansbury L., Lim B., Baskaran V., Lim W. Co-infections in people with COVID-19: a systematic review and meta-analysis. J. Infect. 2020;81(2):266–275. DOI: 10.1016/j.jinf.2020.05.046
Review
For citations:
Zaitsev A.A. Novel coronavirus infection (COVID-19) — clinical recommendations. Clinical Medicine (Russian Journal). 2023;101(12):601-606. (In Russ.) https://doi.org/10.30629/0023-2149-2023-101-12-601-606
Views:
1155
Email this article 